| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
FutureChem Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,330.00 |
| 52 Week High | ₩17,270.00 |
| 52 Week Low | ₩7,610.00 |
| Beta | 1.24 |
| 11 Month Change | -9.77% |
| 3 Month Change | 48.69% |
| 1 Year Change | 85.59% |
| 33 Year Change | 26.94% |
| 5 Year Change | 63.24% |
| Change since IPO | 116.42% |
Recent News & Updates
FutureChemLtd (KOSDAQ:220100) Is In A Good Position To Deliver On Growth Plans
Jun 13
FutureChem Co.,Ltd (KOSDAQ:220100) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Apr 29Revenues Not Telling The Story For FutureChem Co.,Ltd (KOSDAQ:220100)
Feb 26Recent updates
FutureChemLtd (KOSDAQ:220100) Is In A Good Position To Deliver On Growth Plans
Jun 13FutureChem Co.,Ltd (KOSDAQ:220100) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Apr 29Revenues Not Telling The Story For FutureChem Co.,Ltd (KOSDAQ:220100)
Feb 26Is FutureChemLtd (KOSDAQ:220100) Using Debt In A Risky Way?
Feb 05
What Percentage Of FutureChem Co.,Ltd (KOSDAQ:220100) Shares Do Insiders Own?
Dec 14Shareholder Returns
| A220100 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -1.5% | -2.5% | 0.2% |
| 1Y | 85.6% | 0.6% | 7.1% |
Return vs Industry: A220100 exceeded the KR Life Sciences industry which returned 0.6% over the past year.
Return vs Market: A220100 exceeded the KR Market which returned 7.1% over the past year.
Price Volatility
| A220100 volatility | |
|---|---|
| A220100 Average Weekly Movement | 11.3% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A220100's share price has been volatile over the past 3 months.
Volatility Over Time: A220100's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 71 | Dae-Yoon Chi | www.futurechem.co.kr |
FutureChem Co.,Ltd produces and sells radiopharmaceuticals in Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson’s disease; Alzavue, a diagnostic medicine for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303, a diagnostic PET radiopharmaceuticals for the treatment of prostate cancer; 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of atherosclerotic plaque; and 18F-FC211, for the treatment of Alzheimer’s disease.
FutureChem Co.,Ltd Fundamentals Summary
| A220100 fundamental statistics | |
|---|---|
| Market cap | ₩338.75b |
| Earnings (TTM) | -₩7.61b |
| Revenue (TTM) | ₩14.39b |
23.5x
P/S Ratio-44.5x
P/E RatioIs A220100 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A220100 income statement (TTM) | |
|---|---|
| Revenue | ₩14.39b |
| Cost of Revenue | ₩12.75b |
| Gross Profit | ₩1.64b |
| Other Expenses | ₩9.26b |
| Earnings | -₩7.61b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -344.59 |
| Gross Margin | 11.41% |
| Net Profit Margin | -52.91% |
| Debt/Equity Ratio | 0% |
How did A220100 perform over the long term?
See historical performance and comparison